Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on January 30, 2020. The registrant is a Delaware corporation with its principal executive offices in San Diego, CA, and its common stock trades on the Nasdaq Capital Market under the symbol TROV.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
The primary material event reported is the departure of a director:
- Resignation: On January 24, 2020, Dr. Athena Countouriotis resigned as a director of Trovagene, Inc.
- Reason: The resignation was to pursue other opportunities.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the director resignation.
Investor Verification Checklist
- Verify the composition of the Board of Directors following Dr. Countouriotis's resignation.
- Confirm whether a replacement director has been appointed or if the board is operating with a vacancy.
- Review subsequent filings for any impact on the company's strategic direction or governance structure.